CTLA4 and neoplasm: Such effects are exemplified in a recent study in which radiotherapy and dual checkpoint blockade (anti-PD1 plus anti-CTLA-4) demonstrated major tumor regression in metastatic melanoma patients via non-redundant immune mechanisms (111).